Compare GVA & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GVA | GKOS |
|---|---|---|
| Founded | 1922 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.6B |
| IPO Year | 1995 | 2015 |
| Metric | GVA | GKOS |
|---|---|---|
| Price | $123.00 | $98.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | $118.33 | ★ $133.07 |
| AVG Volume (30 Days) | 588.3K | ★ 691.6K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.43% | N/A |
| EPS Growth | ★ 47.33 | N/A |
| EPS | ★ 3.86 | N/A |
| Revenue | ★ $1,762,965,000.00 | $507,442,000.00 |
| Revenue This Year | $13.46 | $23.39 |
| Revenue Next Year | $6.83 | $27.46 |
| P/E Ratio | $31.30 | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $69.08 | $73.16 |
| 52 Week High | $137.24 | $130.23 |
| Indicator | GVA | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 40.30 | 32.70 |
| Support Level | $116.73 | $81.54 |
| Resistance Level | $124.99 | $103.63 |
| Average True Range (ATR) | 3.37 | 3.76 |
| MACD | -1.56 | -2.15 |
| Stochastic Oscillator | 13.12 | 10.81 |
Granite Construction Inc engages in the construction and development of various infrastructure projects on behalf of public and private clients in the United States. It focuses on heavy civil infrastructure projects, including roads, highways, transit facilities, airports, bridges, and other infrastructure projects. In addition, the company performs site preparation and infrastructure services for residential development, energy development, and other facilities. The majority of revenue is derived from the company's Construction operating segment, with the remainder derived from its Materials segment.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.